The Use of Triphenyl Phosphonium Cation Enhances the Mitochondrial Antiplatelet Effect of the Compound Magnolol

Area of Science:

• Mitochondrial biology
• Platelet physiology
• Pharmacology

Background:

• Platelets possess functional mitochondria crucial for their activity.
• Mitochondrial-targeted compounds are explored in cancer, but their platelet effects are understudied.
• Magnolol and its derivatives show potential in inhibiting cancer cell proliferation and inducing ROS/mitophagy.

Purpose of the Study:

• To evaluate the effect of triphenylphosphonium-linked magnolol on human platelets.
• To investigate the impact of magnolol derivatives on platelet mitochondrial function and activity.

Main Methods:

• Synthesis and application of triphenylphosphonium cation linked to magnolol via alkyl chains of varying lengths.
• Assessment of antiplatelet activity and mitochondrial respiration in human-washed platelets.
• Measurement of basal respiration, stimulated respiration (collagen-induced), and ATP-dependent/independent respiration.

Main Results:

• Magnolol linked to triphenylphosphonium via a four-carbon chain (MGN4) enhanced the antiplatelet effect, reducing IC50 by 3-fold.
• Platelets treated with MGN4 (5 µM) exhibited increased basal and collagen-induced respiration.
• MGN4 altered mitochondrial respiration, increasing ATP-independent and non-mitochondrial respiration while decreasing ATP-dependent respiration.

Conclusions:

• The novel compound MGN4 demonstrates a potent antiplatelet effect, superior to magnolol alone.
• MGN4 significantly modulates human platelet mitochondrial respiration, affecting cellular energy dynamics.
• This study highlights the potential of targeted mitochondrial compounds in modulating platelet function.